SG11201804411TA - Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof - Google Patents
Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereofInfo
- Publication number
- SG11201804411TA SG11201804411TA SG11201804411TA SG11201804411TA SG11201804411TA SG 11201804411T A SG11201804411T A SG 11201804411TA SG 11201804411T A SG11201804411T A SG 11201804411TA SG 11201804411T A SG11201804411T A SG 11201804411TA SG 11201804411T A SG11201804411T A SG 11201804411TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- vectors
- compositions
- immunodeficiency virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau rist0) (43) International Publication Date .... ....r .„,„1 22 June 2017(22.06.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/102929 Publication Al Number (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, C07K 14/16 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (21) International Application Number: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, PCT/EP2016/081159 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (22) International Filing Date: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 15 December 2016 (15.12.2016) ZA, ZM, ZW. (25) Filing Language: English (8 4 ) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 15200138.4 15 December 2015 (15.12.2015) EP TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 16194124.0 17 October 2016 (17.10.2016) EP DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (71) Applicant: JANSSEN VACCINES & PREVENTION SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: LANGEDIJK, Johannes, Petrus, Maria; Declarations under Rule 4.17: Archimedesweg 4-6, 2333 CN Leiden (NL). — as to applicant's entitlement to apply for and be granted a (74) Agents: VERHAGE, Richard, A et al.; Archimedesweg patent (Rule 4.170) 4-6, 2333 CN Leiden (NL). — of inventorship (Rule 4.17(iv)) (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, — with international search report (Art 21(3)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, _ with sequence listing part of description (Rule 5.2(a)) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, Il .4t C\ N C\ ei O 1-1 it-- 1-1 (54) Title: HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS, VECTORS, COMPOSITIONS, AND METHODS OF USE 0 THEREOF ei Q (57) : Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15200138 | 2015-12-15 | ||
EP16194124 | 2016-10-17 | ||
PCT/EP2016/081159 WO2017102929A1 (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804411TA true SG11201804411TA (en) | 2018-06-28 |
Family
ID=57737697
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804411TA SG11201804411TA (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
SG10202109457R SG10202109457RA (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202109457R SG10202109457RA (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
Country Status (29)
Country | Link |
---|---|
US (3) | US10369214B2 (en) |
EP (3) | EP3964569A1 (en) |
JP (2) | JP6510149B2 (en) |
KR (1) | KR20180086207A (en) |
CN (2) | CN114686495A (en) |
AU (2) | AU2016369326B2 (en) |
BR (1) | BR112018011122A2 (en) |
CA (1) | CA3008542C (en) |
CY (2) | CY1122705T1 (en) |
DK (2) | DK3584252T3 (en) |
EA (1) | EA038974B1 (en) |
ES (2) | ES2898271T3 (en) |
HR (2) | HRP20211566T1 (en) |
HU (2) | HUE045993T2 (en) |
IL (1) | IL259942B2 (en) |
LT (2) | LT3584252T (en) |
MA (3) | MA44059B1 (en) |
MD (2) | MD3584252T2 (en) |
ME (1) | ME03545B (en) |
MX (2) | MX2018007198A (en) |
PH (1) | PH12018501047A1 (en) |
PL (2) | PL3584252T3 (en) |
PT (1) | PT3390430T (en) |
RS (2) | RS59447B1 (en) |
SG (2) | SG11201804411TA (en) |
SI (2) | SI3584252T1 (en) |
TW (2) | TWI707039B (en) |
WO (1) | WO2017102929A1 (en) |
ZA (1) | ZA201803978B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS61902B1 (en) | 2014-09-26 | 2021-06-30 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
MA40783A (en) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
AU2016369326B2 (en) | 2015-12-15 | 2019-02-21 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
US10273268B2 (en) | 2016-06-16 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
HUE052008T2 (en) | 2016-09-15 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
MA49397A (en) | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | POXVIRUS VECTORS CODING FOR HIV ANTIGENS, AND METHODS FOR USING THEM |
BR112020000867A2 (en) * | 2017-07-19 | 2020-07-21 | Janssen Vaccines & Prevention B.V. | hiv envelope protein mutations stabilizing the trimer |
WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
KR20230019227A (en) * | 2017-11-17 | 2023-02-07 | 그리폴스 다이어그노스틱 솔루션즈 인크. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
CN114269363A (en) * | 2019-04-17 | 2022-04-01 | 威斯达研究所 | Replication-defective adenovirus vectors for HIV vaccine applications |
TW202110476A (en) | 2019-05-22 | 2021-03-16 | 荷蘭商傑森疫苗防護公司 | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
IL292760A (en) | 2019-11-07 | 2022-07-01 | Janssen Vaccines Prevention B V | Protein purification |
EP4149530A1 (en) | 2020-05-12 | 2023-03-22 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
US20220265813A1 (en) | 2021-02-23 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Trimer Stabilizing HIV Envelope Protein Mutation |
WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
ATE519854T1 (en) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | RECOMBINANT ADENOVIRUS BASED ON SEROTYPE 48 (AD48). |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
EP1214333A4 (en) | 1999-09-17 | 2005-01-19 | Dana Farber Cancer Inst Inc | Stabilized soluble glycoprotein trimers |
NZ524661A (en) | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
WO2003004657A1 (en) * | 2001-07-05 | 2003-01-16 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
CA2466413C (en) | 2001-12-04 | 2014-11-04 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
CA2477954C (en) | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
WO2004050856A2 (en) | 2002-12-03 | 2004-06-17 | University Of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
EP2359851A3 (en) | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
CA2539021A1 (en) | 2003-09-15 | 2005-03-31 | Chiron Corporation | Combination approaches for generating immune responses |
US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
EP1737885A2 (en) * | 2004-04-12 | 2007-01-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
JP4772045B2 (en) | 2004-07-16 | 2011-09-14 | アメリカ合衆国 | Vaccine against AIDS containing CMV / R nucleic acid construct |
AU2005279799A1 (en) * | 2004-08-27 | 2006-03-09 | Emory University | Recombinant MVA viruses expressing Clade A/G, Clade B and Clade C modified HIV ENV, GAG and POL genes |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
CN101588813A (en) * | 2005-04-12 | 2009-11-25 | 杜克大学 | Method of inducing neutralizing antibodies to human immunodeficiency virus |
WO2007005934A2 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
EP1917040A4 (en) | 2005-08-23 | 2012-12-12 | Univ California | Polyvalent vaccine |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
EP2040747A4 (en) | 2006-06-19 | 2010-08-25 | Progenics Pharm Inc | Soluble stabilized trimeric hiv env proteins and uses thereof |
CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
EP2137210B1 (en) | 2007-03-02 | 2016-10-19 | GlaxoSmithKline Biologicals SA | Novel method and compositions |
LT3335728T (en) | 2008-10-10 | 2020-03-10 | Children`S Medical Center Corporation | Biochemically stabilized hiv-1 env trimer vaccine |
WO2010059732A1 (en) * | 2008-11-18 | 2010-05-27 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
JP5882741B2 (en) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof |
WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
CN105399833B (en) | 2010-01-04 | 2019-09-06 | Kj 生物科学有限公司 | Dps fusion protein for vaccine and diagnostics |
AU2011209175B2 (en) | 2010-01-28 | 2016-02-04 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
EP3556396B1 (en) | 2010-08-31 | 2022-04-20 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
US9701718B2 (en) | 2010-12-14 | 2017-07-11 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
CN103945864A (en) * | 2011-04-25 | 2014-07-23 | 先进生物学实验室股份有限公司 | Truncated HIV envelope proteins (ENV), methods and compositions related thereto |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
WO2013040766A1 (en) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Method and vaccine capable of inducing broad spectrum immune response against hiv |
EP2766037A4 (en) | 2011-10-12 | 2015-08-05 | Scripps Research Inst | An hiv-1 gp120 mini v3 loop and uses thereof |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
WO2015051270A1 (en) * | 2013-10-04 | 2015-04-09 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
JP2017507672A (en) * | 2014-02-28 | 2017-03-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Replicative recombinant adenoviral vectors, compositions and methods of use thereof |
US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
RS61902B1 (en) | 2014-09-26 | 2021-06-30 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
US20180052173A1 (en) * | 2015-03-18 | 2018-02-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
AU2016369326B2 (en) | 2015-12-15 | 2019-02-21 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
US10273268B2 (en) | 2016-06-16 | 2019-04-30 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
AU2017318689A1 (en) | 2016-09-02 | 2019-04-11 | Beth Israel Deaconess Medical Center, Inc. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
HUE052008T2 (en) | 2016-09-15 | 2021-04-28 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
DE102018124348A1 (en) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Filling box and method for filling containers |
-
2016
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 ES ES19186284T patent/ES2898271T3/en active Active
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/en active Pending
- 2016-12-15 SI SI201631333T patent/SI3584252T1/en unknown
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/en unknown
- 2016-12-15 PL PL19186284T patent/PL3584252T3/en unknown
- 2016-12-15 MX MX2018007198A patent/MX2018007198A/en unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/en unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/en unknown
- 2016-12-15 RS RSP20191399 patent/RS59447B1/en unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/en active Search and Examination
- 2016-12-15 TW TW105141650A patent/TWI707039B/en active
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/en unknown
- 2016-12-15 ES ES16822410T patent/ES2753854T3/en active Active
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/en unknown
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en active Application Filing
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 PL PL16822410T patent/PL3390430T3/en unknown
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/en active Active
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 TW TW109138473A patent/TWI792091B/en active
- 2016-12-15 EA EA201891415A patent/EA038974B1/en unknown
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/en active Active
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/en unknown
- 2016-12-15 PT PT168224103T patent/PT3390430T/en unknown
- 2016-12-15 MA MA44059A patent/MA44059B1/en unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/en unknown
- 2016-12-15 MA MA47522A patent/MA47522B1/en unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 MA MA055825A patent/MA55825A/en unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/en unknown
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/en unknown
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/en unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/en unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/en active
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 DK DK16822410T patent/DK3390430T3/en active
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/en unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/en active Active
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en active Active
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-10-21 HR HRP20191902TT patent/HRP20191902T1/en unknown
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/en unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201810549TA (en) | Hiv vaccine formulation | |
SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
SG11201407586WA (en) | Vaccines for hsv-2 | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations |